Drug Profile
Meningococcal vaccine group C conjugate - Pfizer
Alternative Names: Meningococcal vaccine group C conjugate - Baxter; NeisVac; NeisVac-CLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator North American Vaccine
- Developer Baxter International; Pfizer
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Meningococcal group C infections
Most Recent Events
- 07 Apr 2015 The vaccine is approved for Meningococcal group C infections in Colombia
- 30 Jul 2014 Pfizer acquires Baxter's commercial vaccine business, including meningococcal vaccine group C conjugate NeisVac-C
- 18 Feb 2013 Discontinued - Phase-III for Meningococcal group C infections in USA (IM)